Massularia acuminata for Health & Longevity - Quick Reference Sheet

Massularia acuminata for Health & Longevity

Created on 10/18/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Gemini 4 Argon – Audit

Massularia acuminata is a West African tree used for tooth cleaning and marketed as an oral extract for male hormone and sexual support. Human trials test only children's chewing sticks, with conflicted gum results matching toothbrushing. Oral benefits rest on rodent and cell studies, which also show liver, kidney, heart, and testicular damage from prolonged or high doses, requiring strict dose limits, short cycles, and blood monitoring. (Full Review)

Protocol

Allometric oral extract dosing
550–900 mg daily
Scaled from 50 mg/kg rat dose (no human trials): 550 mg (68 kg), 700 mg (91 kg), 900 mg (113 kg); ≤550 mg for older adults
Best time of day
Morning with food
Aligns with diurnal LH and testosterone secretion peaks while minimizing gastrointestinal irritation from saponins and tannins
Single vs. split dosing
Split doses >500 mg (5–21 days)
Morning and early-afternoon administration for gastrointestinal comfort across 5- to 21-day oral protocols; chewing sticks used once daily without ingestion
Time to effect
Gingival Health and Plaque Control
6–12 weeks
Daily chewing-stick use in 6-week and 3-month pediatric dental trials
Testosterone and Gonadotropin Elevation
1–21 days (rats)
Serum testosterone and LH rose in 1–5 day and 21-day male rat studies; not studied in humans
Erectile Function and Sexual Behavior Enhancement
1–5 days (rats)
Mounting and copulatory activity rose within 1–5 days in male rats; not studied in humans

Benefits

Contraindications
  • Individuals with hepatic impairment, elevated liver transaminases, or chronic kidney disease
  • Individuals with cardiovascular disease or arrhythmias
  • Men with prostate cancer, breast cancer, or severe BPH, and women who are pregnant, breastfeeding, or have hormone-sensitive conditions
  • Men actively pursuing fertility
Key Interactions
  • PDE-5 inhibitors (sildenafil, tadalafil, vardenafil): Caution / Monitor (theoretical)
  • Antidiabetic medications (metformin, glimepiride, insulin): Monitor (theoretical)
  • Androgen therapies and 5-alpha-reductase inhibitors (testosterone cypionate, clomiphene, finasteride): Avoid (theoretical)
  • Hepatotoxic prescription medications (atorvastatin, methotrexate, isoniazid): Avoid (theoretical)
  • Over-the-counter analgesics and anti-inflammatories (acetaminophen, ibuprofen, naproxen): Caution (theoretical)
  • Androgen-modulating and NO-boosting supplements (Tongkat Ali, Fadogia agrestis, L-citrulline): Caution (theoretical)
  • Ethanol (alcoholic beverages): Avoid (theoretical)

Risk & Side Effects

  • High:
  • Medium:
  • Low:
  • Speculative: Hepatotoxicity and liver enzyme alterations; high-dose testicular atrophy and impaired spermatogenesis; nephrotoxicity and electrolyte imbalance; myocardial inflammation

Monitoring

Marker Target Why
Serum Total Testosterone (males) 264–916 ng/dL (standard reference range) Expected-change and safety marker: tracks androgenic response or high-dose suppression.
Luteinizing Hormone (LH) & Follicle-Stimulating Hormone (FSH) LH: 1.7–8.6 mIU/mL; FSH: 1.5–12.4 mIU/mL (standard reference range) Expected-change and safety marker: monitors pituitary stimulation versus chronic suppression.
Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) & Total Bilirubin ALT: 7–56 U/L; AST: 8–33 U/L; Bilirubin: 0.1–1.2 mg/dL (standard reference range) Safety check: detects preclinical hepatocyte injury or biliary stress; elevation halts use.
Serum Creatinine & Blood Urea Nitrogen (BUN) Creatinine: 0.7–1.3 mg/dL; BUN: 7–20 mg/dL (standard reference range) Safety check: detects glomerular or tubular nephrotoxicity; elevation above baseline halts use.
Glycated Hemoglobin (HbA1c) 4.0%–5.6% (standard reference range) Expected-change marker: tracks glycemic modulation observed in diabetic rodent models.

Cadence: Baseline morning fasting draw before initiation; repeat hepatic and renal safety panels at 2–3 weeks (cycle completion), hormone and glycemic markers at 3–4 weeks (8–12 weeks for HbA1c), and every 3–6 months across repeated cycles.

Qualitative Assessment

  • Erectile function: Weekly tracking of morning erections, rigidity, and libido.
  • Gingival health: Six- to twelve-week tracking of gum bleeding and plaque.
  • Digestive tolerance: Daily tracking for nausea, dark urine, or abdominal discomfort.
  • Sleep and energy: Daily tracking of daytime vitality and sleep onset.